Drug manufacturers are striving to innovate, aiming to match industry leaders Eli Lilly and Novo Nordisk in the field of weight-loss treatments. They seek to offer an improved experience for patients.

The surge in popularity of new weight-loss drugs often overshadows their drawbacks. Weekly injections can be inconvenient for patients, and these treatments may cause unpleasant gastrointestinal side effects. Additionally, some drugs have been associated with muscle and bone loss.

This backdrop has set the stage for a competitive race among pharmaceutical companies focused on delivering more effective and user-friendly solutions.